Abstract
Inflammation is considered a hallmark of cancer. The chronic inflammatory process is driven by the interaction of cells, proteins, cytokines, transcription factors, and lipid mediators within the tumor microenvironment giving rise to complex pro-inflammatory cascades. These can be inhibited by a variety of different anti-inflammatory compounds, like non-steroidal anti-inflammatory drugs, glucocorticoids, anti-inflammatory biologicals, phytotherapeutics (mainly polyphenols), and drugs with pleiotropic anti-inflammatory effects. In general, it appears that the anti-tumor activity of these compounds occurs at higher doses than the doses used in conventional anti-inflammatory therapy. To optimally take advantage of the anti-tumor activity and at the same time limit side effects, targeted delivery of anti-inflammatory drugs appears an attractive approach.
Current Pharmaceutical Design
Title: Targeted Delivery of Anti-Inflammatory Agents to Tumors
Volume: 15 Issue: 16
Author(s): Maria Coimbra, Sylvia A. Kuijpers, Sebastiaan P. van Seters, Gert Storm and Raymond M. Schiffelers
Affiliation:
Abstract: Inflammation is considered a hallmark of cancer. The chronic inflammatory process is driven by the interaction of cells, proteins, cytokines, transcription factors, and lipid mediators within the tumor microenvironment giving rise to complex pro-inflammatory cascades. These can be inhibited by a variety of different anti-inflammatory compounds, like non-steroidal anti-inflammatory drugs, glucocorticoids, anti-inflammatory biologicals, phytotherapeutics (mainly polyphenols), and drugs with pleiotropic anti-inflammatory effects. In general, it appears that the anti-tumor activity of these compounds occurs at higher doses than the doses used in conventional anti-inflammatory therapy. To optimally take advantage of the anti-tumor activity and at the same time limit side effects, targeted delivery of anti-inflammatory drugs appears an attractive approach.
Export Options
About this article
Cite this article as:
Coimbra Maria, Kuijpers A. Sylvia, van Seters P. Sebastiaan, Storm Gert and Schiffelers M. Raymond, Targeted Delivery of Anti-Inflammatory Agents to Tumors, Current Pharmaceutical Design 2009; 15 (16) . https://dx.doi.org/10.2174/138161209788453220
DOI https://dx.doi.org/10.2174/138161209788453220 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Extranuclear Effects of Thyroid Hormones in Skeletal Muscle
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Molecular Treatment of Different Breast Cancers
Anti-Cancer Agents in Medicinal Chemistry CASC15: A Tumor-Associated Long Non-Coding RNA
Current Pharmaceutical Design Frequency Domain Mapping of Atrial Fibrillation - Methodology, Experimental Data and Clinical Implications
Current Cardiology Reviews Mechanisms of Melatonin in Alleviating Alzheimer’s Disease
Current Neuropharmacology Nanocarriers for Tracking and Treating Diseases
Current Medicinal Chemistry Elevated Heart Rate, A Risk Factor and Risk Marker of Cardiovascular Disease
Current Hypertension Reviews Pathophysiology of Chronic Obstructive Pulmonary Disease
Current Respiratory Medicine Reviews Effect of Simvastatin use on Autonomic Function in Patients with End Stage Renal Disease
Cardiovascular & Hematological Disorders-Drug Targets Clinical Pharmacokinetics of Systemically Administered Antimycotics
Current Clinical Pharmacology Medical Management of the Diabetic Patient with Coronary Artery Disease
Current Pharmaceutical Design Omega-3 Fatty Acids: Role in Metabolism and Cardiovascular Disease
Current Pharmaceutical Design WITHDRAWN: ESBLA: An Edge-Significance Based Modified Louvain Algorithm for Event Detection from Tweets
Recent Advances in Computer Science and Communications Ellipticines as DNA-Targeted Chemotherapeutics
Current Medicinal Chemistry The Role of Beta-Blocker in Heart Failure in Adults with Congenital Heart Disease
Reviews on Recent Clinical Trials Improved Pharmacokinetic Profile and Anti-Inflammatory Property of a Novel Curcumin Derivative, A50
Letters in Drug Design & Discovery Levosimendan: A New Inodilatory Drug for the Treatment of Decompensated Heart Failure
Current Pharmaceutical Design Role of microRNAs in Hepatic Stellate Cells and Hepatic Fibrosis: An Update
Current Pharmaceutical Design Aspirin Intolerance: Experimental Models for Bed-to-Bench
Current Drug Targets Recent Advances in Molecular Modeling and Medicinal Chemistry Aspects of Phospho-Glycoprotein&#
Current Drug Metabolism